The role of sphingosine-1-phosphate receptor modulators in the prevention of transplant rejection and autoimmune diseases

Current Opinion in Investigational Drugs

Volumn 10, Issue 11, 2009, Pages 1183-1194

  Japtok, L ^a   Kleuser, B ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Clinical trial; Fingolimod; KRP 203; Lymphopenia; Multiple sclerosis; S1P 1 receptor subtype

Indexed keywords

2 AMINO 2 [2 [4 (3 BENZYLOXYPHENYLTHIO) 2 CHLOROPHENYL]ETHYL] 1,3 PROPANEDIOL; 3 [2 (3 TRIFLUOROMETHYL 4 BIPHENYLYL)BENZO[B]THIEN 5 YLMETHYLAMINO]PROPIONIC ACID; 5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; BETA INTERFERON; BETA1A INTERFERON; CMY 5442; CYCLOSPORIN; CYM 5442; FINGOLIMOD; GLATIRAMER; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PLACEBO; RECEPTOR SUBTYPE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ALLERGIC ENCEPHALOMYELITIS; ARTHRITIS; ASTHMA; AUTOIMMUNE DISEASE; BLOOD PRESSURE; CARDIAC GRAFT REJECTION; CLINICAL TRIAL; COLITIS; CONTACT DERMATITIS; DIABETIC ANGIOPATHY; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; DYSPNEA; GRAFT REJECTION; HEART RATE; HEPATITIS; HERPES VIRUS INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAUNDICE; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; MYOCARDITIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETINA MACULA EDEMA; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SKIN CANCER; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; UVEORETINITIS;

ANIMALS; AUTOIMMUNE DISEASES; CELL MOVEMENT; CLINICAL TRIALS AS TOPIC; GRAFT REJECTION; HUMANS; LYMPHOCYTES; MULTIPLE SCLEROSIS; ORGAN TRANSPLANTATION; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION;

EID: 70449350810     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S: Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta (2006) 1758(12):2016-2026.
2. Hannun YA, Obeid LM: Principles of bioactive lipid signaling: Lessons from sphingolipids. Nat Rev Mol Cell Biol (2008) 9(2):139-150.
3. Spiegel S, Milstien S: Sphingosine-1-phosphate: An enigmatic signaling lipid. Nat Rev Mol Cell Biol (2003) 4(5):397-407.
4. Alemany R, van Koppen CJ, Danneberg K, Ter Braak M, Meyer Zu Heringdorf D: Regulation and functional roles of sphingosine kinases. Naunyn Schmiedebergs Arch Pharmacol (2007) 374(5-6):413-428.
5. Olivera A, Spiegel S: Sphingosine kinase: A mediator of vital cellular functions. Prostaglandins (2001) 64(1-4):123-134.
6. Yu H, Okada T, Kobayashi M, Abo-Elmatty DM, Jahangeer S, Nakamura S: Roles of extracellular and intracellular sphingosine 1-phosphate in cell migration. Genes Cells (2009) 14(5):597-605.
7. Chun J, Goetzl EJ, Hla T, Igarashi Y, Lynch KR, Moolenaar W, Pyne S, Tigyi G: International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev (2002) 54(2):265-269.
8. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA et al: The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem (2002) 277(24):21453-21457.
9. Jo SK, Bajwa A, Ye H, Vergis AL, Awad AS, Kharel Y, Lynch KR, Okusa MD: Divergent roles of sphingosine kinases in kidney ischemia-reperfusion injury. Kidney Int (2009) 75(2):167-175.
10. Zemann B, Kinzel B, Müller M, Reuschel R, Mechtcheriakova D, Urtz N, Bornancin F, Baumruker T, Billich A: Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood (2006) 107(4):1454-1458.
11. Gräler MH, Goetzl EJ: The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J (2004) 18(3):551-553.
12. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG: Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature (2004) 427(6972):355-360.
13. Mullershausen F, Zecri F, Cetin C, Billich A, Guerini D, Seuwen K: Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol (2009) 5(6):428-434.
14. Huwiler A, Kolter T, Pfeilschifter J, Sandhoff K: Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta (2000) 1485(2-3):63-99.
15. Le Stunff H, Mikami A, Giussani P, Hobson JP, Jolly PS, Milstien S, Spiegel S: Role of sphingosine-1-phosphate phosphatase 1 in epidermal growth factor-induced chemotaxis. J Biol Chem (2004) 279(33):34290-34297.
16. Merrill AH Jr: De novo sphingolipid biosynthesis: A necessary, but dangerous, pathway. J Biol Chem (2002) 277(29):25843-25846.
17. Kihara A, Anada Y, Igarashi Y: Mouse sphingosine kinase isoforms SphK1a and SphK1b differ in enzymatic traits including stability, localization, modifcation, and oligomerization. J Biol Chem (2006) 281(7):4532-4539.
18. Liu H, Toman RE, Goparaju SK, Maceyka M, Nava VE, Sankala H, Payne SG, Bektas M, Ishii I, Chun J, Milstein S et al: Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis. J Biol Chem (2003) 278(41):40330-40336.
19. Venkataraman K, Thangada S, Michaud J, Oo ML, Ai Y, Lee YM, Wu M, Parikh NS, Khan F, Proia RL, Hla T: Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. Biochem J (2006) 397(3):461-471.
20. Ding G, Sonoda H, Yu H, Kajimoto T, Goparaju SK, Jahangeer S, Okada T, Nakamura S: Protein kinase D-mediated phosphorylation and nuclear export of sphingosine kinase 2. J Biol Chem (2007) 282(37):27493-27502.
21. Okada T, Ding G, Sonoda H, Kajimoto T, Haga Y, Khosrowbeygi A, Gao S, Miwa N, Jahangeer S, Nakamura S: Involvement of N-terminal-extended form of sphingosine kinase 2 in serum-dependent regulation of cell proliferation and apoptosis. J Biol Chem (2005) 280(43):36318-36325.
22. Mandala SM, Thornton R, Galve-Roperh I, Poulton S, Peterson C, Olivera A, Bergstrom J, Kurtz MB, Spiegel S: Molecular cloning and characterization of a lipid phosphohydrolase that degrades sphingosine-1- phosphate and induces cell death. Proc Natl Acad Sci USA (2000) 97(14):7859-7864.
23. Ogawa C, Kihara A, Gokoh M, Igarashi Y: Identifcation and characterization of a novel human sphingosine-1-phosphate phosphohydrolase, hSPP2. J Biol Chem (2003) 278(2): 1268-1272.
24. Van Veldhoven PP, Mannaerts GP: Sphinganine 1-phosphate metabolism in cultured skin fbroblasts: Evidence for the existence of a sphingosine phosphatase. Biochem J (1994) 299(Pt 3):597-601.
25. Murata N, Sato K, Kon J, Tomura H, Yanagita M, Kuwabara A, Ui M, Okajima F: Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J (2000) 352 (Pt 3):809-815.
26. Caligan TB, Peters K, Ou J, Wang E, Saba J, Merrill AH Jr: A high-performance liquid chromatographic method to measure sphingosine 1-phosphate and related compounds from sphingosine kinase assays and other biological samples. Anal Biochem (2000) 281(1):36-44.
27. Edsall LC, Spiegel S: Enzymatic measurement of sphingosine 1-phosphate. Anal Biochem (1999) 272(1):80-86.
28. Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG: Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science (2005) 309(5741): 1735-1739.
29. Aoki S, Yatomi Y, Ohta M, Osada M, Kazama F, Satoh K, Nakahara K, Ozaki Y: Sphingosine 1-phosphate-related metabolism in the blood vessel. J Biochem (2005) 138(1):47-55.
30. Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, Camerer E, Zheng YW, Huang Y, Cyster JG, Coughlin SR: Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science (2007) 316(5822):295-298.
31. Hänel P, Andréani P, Gräler MH: Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J (2007) 21(4): 1202-1209.
32. Ito K, Anada Y, Tani M, Ikeda M, Sano T, Kihara A, Igarashi Y: Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes. Biochem Biophys Res Commun (2007) 357(1):212-217.
33. Venkataraman K, Lee YM, Michaud J, Thangada S, Ai Y, Bonkovsky HL, Parikh NS, Habrukowich C, Hla T: Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res (2008) 102(6):669-676.
34. Hla T: Sphingosine 1-phosphate receptors. Prostaglandins (2001) 64(1-4):135-142.
35. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, Rosenfeldt HM, Nava VE, Chae SS, Lee MJ, Liu CH et al: Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest (2000) 106(8):951-961.
36. Oyama O, Sugimoto N, Qi X, Takuwa N, Mizugishi K, Koizumi J, Takuwa Y: The lysophospholipid mediator sphingosine-1-phosphate promotes angiogenesis in vivo in ischaemic hindlimbs of mice. Cardiovasc Res (2008) 78(2):301-307.
37. Niessen F, Furlan-Freguia C, Fernandez JA, Mosnier LO, Castellino FJ, Weiler H, Rosen H, Griffn JH, Ruf W: Endogenous EPCR/aPC-PAR1 signaling prevents infammation-induced vascular leakage and lethality. Blood (2009) 113(12):2859-2866.
38. Radeke HH, von Wenckstern H, Stoidtner K, Sauer B, Hammer S, Kleuser B: Overlapping signaling pathways of sphingosine 1-phosphate and TGF-? in the murine Langerhans cell line XS52. J Immunol (2005) 174(5):2778-2786.
39. Sanna MG, Wang SK, Gonzalez-Cabrera PJ, Don A, Marsolais D, Matheu MP, Wei SH, Parker I, Jo E, Cheng WC, Cahalan MD et al: Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol (2006) 2(8):434-441.
40. Singleton PA, Chatchavalvanich S, Fu P, Xing J, Birukova AA, Fortune JA, Klibanov AM, Garcia JG, Birukov KG: Akt-mediated transactivation of the S1P1 receptor in caveolin-enriched microdomains regulates endothelial barrier enhancement by oxidized phospholipids. Circ Res (2009) 104(8):978-986.
41. Liu G, Burns S, Huang G, Boyd K, Proia RL, Flavell RA, Chi H: The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. Nat Immunol (2009) 10(7):769-777.
42. Pyne NJ, Waters C, Moughal NA, Sambi BS, Pyne S: Receptor tyrosine kinase-GPCR signal complexes. Biochem Soc Trans (2003) 31(Pt 6):1220-1225.
43. Sauer B, Vogler R, von Wenckstern H, Fujii M, Anzano MB, Glick AB, Schafer-Korting M, Roberts AB, Kleuser B: Involvement of Smad signaling in sphingosine 1-phosphate-mediated biological responses of keratinocytes. J Biol Chem (2004) 279(37):38471-38479.
44. Herr DR, Grillet N, Schwander M, Rivera R, Muller U, Chun J: Sphingosine 1-phosphate (S1P) signaling is required for maintenance of hair cells mainly via activation of S1P2. J Neurosci (2007) 27(6):1474-1478.
45. Kono M, Belyantseva IA, Skoura A, Frolenkov GI, Starost MF, Dreier JL, Lidington D, Bolz SS, Friedman TB, Hla T, Proia RL: Deafness and stria vascularis defects in S1P2 receptor-null mice. J Biol Chem (2007) 282(14):10690-10696.
46. MacLennan AJ, Carney PR, Zhu WJ, Chaves AH, Garcia J, Grimes JR, Anderson KJ, Roper SN, Lee N: An essential role for H218/AGR16/Edg-5/LP(B2) sphingosine 1-phosphate receptor in neuronal excitability. Eur J Neurosci (2001) 14(2): 203-209.
47. Ishii I, Friedman B, Ye X, Kawamura S, McGiffert C, Contos JJ, Kingsbury MA, Zhang G, Brown JH, Chun J: Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP(B3)/EDG-3. J Biol Chem (2001) 276(36):33697-33704.
48. Kono M, Mi Y, Liu Y, Sasaki T, Allende ML, Wu YP, Yamashita T, Proia RL: The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis. J Biol Chem (2004) 279(28):29367-29373.
49. Gon Y, Wood MR, Kiosses WB, Jo E, Sanna MG, Chun J, Rosen H: S1P3 receptor-induced reorganization of epithelial tight junctions compromises lung barrier integrity and is potentiated by TNF. Proc Natl Acad Sci USA (2005) 102(26): 9270-9275.
50. Graler MH, Grosse R, Kusch A, Kremmer E, Gudermann T, Lipp M: The sphingosine 1-phosphate receptor S1P4 regulates cell shape and motility via coupling to Gi and G12/13. J Cell Biochem (2003) 89(3):507-519.
51. Wang W, Graeler MH, Goetzl EJ: Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P4) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration. FASEB J (2005) 19(12):1731-1733.
52. Im DS, Clemens J, Macdonald TL, Lynch KR: Characterization of the human and mouse sphingosine 1-phosphate receptor, S1P(5) (Edg-8): Structure-activity relationship of sphingosine1-phosphate receptors. Biochemistry (2001) 40(46):14053-14060.
53. Jaillard C, Harrison S, Stankoff B, Aigrot MS, Calver AR, Duddy G, Walsh FS, Pangalos MN, Arimura N, Kaibuchi K, Zalc B et al: Edg8/S1P5: An oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci (2005) 25(6): 1459-1469.
54. Walzer T, Chiossone L, Chaix J, Calver A, Carozzo C, Garrigue-Antar L, Jacques Y, Baratin M, Tomasello E, Vivier E: Natural killer cell traffcking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat Immunol (2007) 8(12):1337-1344.
55. Nixon GF: Sphingolipids in infammation: Pathological implications and potential therapeutic targets. Br J Pharmacol (2009):doi:10.1111/j.1476-5381. 2009.00281.
56. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, Rosenbach M et al: Alteration of lymphocyte traffcking by sphingosine-1-phosphate receptor agonists. Science (2002) 296(5566):346-349.
57. Rosen H, Sanna G, Alfonso C: Egress: A receptor-regulated step in lymphocyte traffcking. Immunol Rev (2003) 195:160-177.
58. Bolick DT, Srinivasan S, Kim KW, Hatley ME, Clemens JJ, Whetzel A, Ferger N, Macdonald TL, Davis MD, Tsao PS, Lynch KR et al: Sphingosine-1-phosphate prevents tumor necrosis factor-?-mediated monocyte adhesion to aortic endothelium in mice. Arterioscler Thromb Vasc Biol (2005) 25(5):976-981.
59. Lien YH, Yong KC, Cho C, Igarashi S, Lai LW: S1P1-selective agonist, SEW2871, ameliorates ischemic acute renal failure. Kidney Int (2006) 69(9):1601-1608.
60. Okazaki M, Kreisel F, Richardson SB, Kreisel D, Krupnick AS, Patterson GA, Gelman AE: Sphingosine 1-phosphate inhibits ischemia reperfusion injury following experimental lung transplantation. Am J Transplant (2007) 7(4):751-758.
61. Matsuyuki H, Maeda Y, Yano K, Sugahara K, Chiba K, Kohno T, Igarashi Y: Involvement of sphingosine 1-phosphate (S1P) receptor type 1 and type 4 in migratory response of mouse T cells toward S1P. Cell Mol Immunol (2006) 3(6):429-437.
62. Allende ML, Dreier JL, Mandala S, Proia RL: Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem (2004) 279(15):15396-15401.
63. Kabashima K, Haynes NM, Xu Y, Nutt SL, Allende ML, Proia RL, Cyster JG: Plasma cell S1P expression determines secondary lymphoid organ retention versus bone marrow tropism. J Exp Med (2006) 203(12):2683-2690.
64. Martino A: Sphingosine 1-phosphate as a novel immune regulator of dendritic cells. J Biosci (2007) 32(6):1207-1212.
65. Idzko M, Hammad H, van Nimwegen M, Kool M, Muller T, Soullie T, Willart MA, Hijdra D, Hoogsteden HC, Lambrecht BN: Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. J Clin Invest (2006) 116(11):2935-2944.
66. Reines I, Kietzmann M, Mischke R, Tschernig T, Luth A, Kleuser B, Baumer W: Topical application of sphingosine-1-phosphate and FTY720 attenuate allergic contact dermatitis reaction through inhibition of dendritic cell migration. J Invest Dermatol (2009) 129(8):1954-1962.
67. Prieschl EE, Csonga R, Novotny V, Kikuchi GE, Baumruker T: The balance between sphingosine and sphingosine-1-phosphate is decisive for mast cell activation after Fce receptor I triggering. J Exp Med (1999) 190(1):1-8.
68. Jolly PS, Bektas M, Olivera A, Gonzalez-Espinosa C, Proia RL, Rivera J, Milstien S, Spiegel S: Transactivation of sphingosine-1-phosphate receptors by Fc RI triggering is required for normal mast cell degranulation and chemotaxis. J Exp Med (2004) 199(7):959-970.
69. Camerer E, Regard JB, Cornelissen I, Srinivasan Y, Duong DN, Palmer D, Pham TH, Wong JS, Pappu R, Coughlin SR: Sphingosine-1-phosphate in the plasma compartment regulates basal and infammation-induced vascular leak in mice. J Clin Invest (2009) 119(7):1871-1879.
70. Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, Ye SQ, Garcia JG: Activated protein C mediates novel lung endothelial barrier enhancement: Role of sphingosine 1-phosphate receptor transactivation. J Biol Chem (2005) 280(17):17286-17293.
71. Sanchez T, Skoura A, Wu MT, Casserly B, Harrington EO, Hla T: Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P R) and its downstream effectors ROCK and PTEN. Arterioscler Thromb Vasc Biol (2007) 27(6):1312-1318.
72. Singleton PA, Moreno-Vinasco L, Sammani S, Wanderling SL, Moss J, Garcia JG: Attenuation of vascular permeability by methylnaltrexone: Role of mOP-R and S1P transactivation. Am J Respir Cell Mol Biol (2007) 37(2):222-231.
73. Aoki S, Yatomi Y, Shimosawa T, Yamashita H, Kitayama J, Tsuno NH, Takahashi K, Ozaki Y: The suppressive effect of sphingosine 1-phosphate on monocyte-endothelium adhesion may be mediated by the rearrangement of the endothelial integrins a5P1 and avp3. J Thromb Haemost (2007) 5(6): 1292-1301.
74. Fujita T, Inoue K, Yamamoto S, Ikumoto T, Sasaki S, Toyama R, Chiba K, Hoshino Y, Okumoto T: Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot (Tokyo) (1994) 47(2):208-215.
75. von Wenckstern H, Zimmermann K, Kleuser B: The role of the lysophospholipid sphingosine 1-phosphate in immune cell biology. Arch Immunol Ther Exp (2006) 54(4):239-251.
76. Kahan BD, Karlix JL, Ferguson RM, Leichtman AB, Mulgaonkar S, Gonwa TA, Skerjanec A, Schmouder RL, Chodoff L: Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: A multicenter, randomized, placebo-controlled, phase I study. Transplantation (2003) 76(7):1079-1084.
77. Budde K, Schmouder RL, Nashan B, Brunkhorst R, Lücker PW, Mayer T, Brookman L, Nedelman J, Skerjanec A, Böhler T, Neumayer HH: Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. Am J Transplant (2003) 3(7):846-854.
78. Sanchez T, Estrada-Hernandez T, Paik JH, Wu MT, Venkataraman K, Brinkmann V, Claffey K, Hla T: Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem (2003) 278(47):47281-47290.
79. Wei SH, Rosen H, Matheu MP, Sanna MG, Wang SK, Jo E, Wong CH, Parker I, Cahalan MD: Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat Immunol (2005) 6(12):1228-1235.
80. Suleiman M, Cury PM, Pestana JO, Burdmann EA, Bueno V: FTY720 prevents renal T-cell infltration after ischemia/reperfusion injury. Transplant Proc (2005) 37(1):373-374.
81. Kaudel CP, Frink M, Schmiddem U, Probst C, Bergmann S, Krettek C, Klempnauer J, van Griensven M, Winkler M: FTY720 for treatment of ischemia-reperfusion injury following complete renal ischemia; impact on long-term survival and T-lymphocyte tissue infltration. Transplant Proc (2007) 39(2):499-502.
82. Mulgaonkar S, Tedesco H, Oppenheimer F, Walker R, Kunzendorf U, Russ G, Knofach A, Patel Y, Ferguson R: FTY720/cyclosporine regimens in de novo renal transplantation: A 1-year dose-fnding study. Am J Transplant (2006) 6(8):1848-1857.
83. Tedesco-Silva H, Mourad G, Kahan BD, Boira JG, Weimar W, Mulgaonkar S, Nashan B, Madsen S, Charpentier B, Pellet P, Vanrenterghem Y: FTY720, a novel immunomodulator: Effcacy and safety results from the frst phase 2A study in de novo renal transplantation. Transplantation (2005) 79(11): 1553-1560.
84. Budde K, Schmouder RL, Brunkhorst R, Nashan B, Lücker PW, Mayer T, Choudhury S, Skerjanec A, Kraus G, Neumayer HH: First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol (2002) 13(4): 1073-1083.
85. Tawadrous MN, Mabuchi A, Zimmermann A, Wheatley AM: Effects of immunosuppressant FTY720 on renal and hepatic hemodynamics in the rat. Transplantation (2002) 74(5):602-610.
86. Gennero I, Fauvel J, Nieto M, Cariven C, Gaits F, Briand-Mésange F, Chap H, Salles JP: Apoptotic effect of sphingosine 1-phosphate and increased sphingosine 1-phosphate hydrolysis on mesangial cells cultured at low cell density. J Biol Chem (2002) 277(15):12724-12734.
87. Hanafusa N, Yatomi Y, Yamada K, Hori Y, Nangaku M, Okuda T, Fujita T, Kurokawa K, Fukagawa M: Sphingosine 1-phosphate stimulates rat mesangial cell proliferation from outside the cells. Nephrol Dial Transplant (2002) 17(4):580-586.
88. Katsuma S, Hada Y, Ueda T, Shiojima S, Hirasawa A, Tanoue A, Takagaki K, Ohgi T, Yano J, Tsujimoto G: Signaling mechanisms in sphingosine 1-phosphate-promoted mesangial cell proliferation. Genes Cells (2002) 7(12):1217-1230.
89. Xin C, Ren S, Eberhardt W, Pfeilschifter J, Huwiler A: The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signaling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells. Br J Pharmacol (2005) 147(2)164-174.
90. Xin C, Ren S, Kleuser B, Shabahang S, Eberhardt W, Radeke H, Schafer-Korting M, Pfeilschifter J, Huwiler A: Sphingosine 1-phosphate cross-activates the Smad signaling cascade and mimics transforming growth factor-?-induced cell responses. J Biol Chem (2004) 279(34):35255-35262.
91. Landeen DK, Bederko DA, Kondo CS, Hu BS, Aroonsakool N, Haga JH, Giles WR: Mechanisms of the negative inotropic effects of sphingosine-1-phosphate on adult mouse ventricular myocytes. Am J Physiol Heart Circ Physiol (2008) 294(2): H736-H749.
92. Salvadori M, Budde K, Charpentier B, Klempnauer J, Nashan B, Pallardo LM, Eris J, Schena FP, Eisenberger U, Rostaing L, Hmissi A et al: FTY720 versus MMF with cyclosporine in de novo renal transplantation: A 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant (2006) 6(12): 2912-2921.
93. Tedesco-Silva H, Pescovitz MD, Cibrik D, Rees MA, Mulgaonkar S, Kahan BD, Gugliuzza KK, Rajagopalan PR, Esmeraldo Rde M, Lord H, Salvadori M et al: Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation (2006) 82(12):1689-1697.
94. Fujishiro J, Kudou S, Iwai S, Takahashi M, Hakamata Y, Kinoshita M, Iwanami S, Izawa S, Yasue T, Hashizume K, Murakami T et al: Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation. Transplantation (2006) 82(6):804-812.
95. Suzuki C, Takahashi M, Morimoto H, Izawa A, Ise H, Fujishiro J, Murakami T, Ishiyama J, Nakada A, Nakayama J, Shimada K et al: Effcacy of mycophenolic acid combined with KRP-203, a novel immunomodulator, in a rat heart transplantation model. J Heart Lung Transplant (2006) 25(3):302-309.
96. Takahashi M, Shimizu H, Murakami T, Enosawa S, Suzuki C, Takeno Y, Hakamata Y, Kudou S, Izawa S, Yasue T, Kobayashi E: A novel immunomodulator KRP-203 combined with cyclosporine prolonged graft survival and abrogated transplant vasculopathy in rat heart allografts. Transplant Proc (2005) 37(1):143-145.
97. Shimizu H, Takahashi M, Kaneko T, Murakami T, Hakamata Y, Kudou S, Kishi T, Fukuchi K, Iwanami S, Kuriyama K, Yasue T et al: KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation (2005) 111(2):222-229.
98. Fujishiro J, Suzuki C, Kudou S, Yasue T, Hakamata Y, Takahashi M, Murakami T, Hashizume K, Kobayashi E: Change from cyclosporine to combination therapy of mycophenolic acid with the new sphingosine-1-phosphate receptor agonist, KRP-203, prevents host nephrotoxicity and transplant vasculopathy in rats. J Heart Lung Transplant (2006) 25(7):825-833.
99. Pan S, Mi Y, Pally C, Beerli C, Chen A, Guerini D, Hinterding K, Nuesslein-Hildesheim B, Tuntland T, Lefebvre S, Liu Y et al: A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol (2006) 13(11):1227-1234.
100. Gonsette RE: Neurodegeneration in multiple sclerosis: The role of oxidative stress and excitotoxicity. J Neurol Sci (2008) 274(1-2):48-53.
101. Friese MA, Fugger L: Pathogenic CD8+ T cells in multiple sclerosis. Ann Neurol (2009) 66(2):132-141.
102. Korn T: Pathophysiology of multiple sclerosis. J Neurol (2008) 255(Suppl 6):2-6.
103. Trapp BD, Stys PK: Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol (2009) 8(3):280-291.
104. Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S: Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology (2002) 58(2):169-178.
105. Tysabri (natalizumab): Biogen Idec, Cambridge, MA, USA/Elan Pharmaceuticals Inc, San Francisco, CA, USA (2009). www.tysabri. com/tysbProject/tysb.portal/-baseurl/threeColLayout/SCSRepository/ en-US/tysb/home/index.xml
106. Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O'Connor PW, Phillips JT et al: The effcacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 256(3):405-415.
107. Hafer DA: Multiple sclerosis. J Clin Invest (2004) 113:788-794.
108. Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G, Hoyer D, Mir A: Brain sphingosine-1-phosphate receptors: Implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther (2008) 117(1):77-93.
109. O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L: Oral fngolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study. Neurology (2009) 72(1):73-79.
110. No authors listed: Trial watch: Phase III promise for oral multiple sclerosis therapy. Nat Rev Drug Discov (2009) 8(2):98.
111. Cohen J, Pelletier J, Kappos L, Montalban X, Hartung H-P, Comi G, Khatri BO, Barkhof F, Stites T, Jin J, Wu S et al: Oral fngolimod (FTY-720) versus interferon ?-1a in replapsing-remitting multiple sclerosis: Results from a phase III study (TRANSFORMS). American Academy of Neurology Annual Meeting, Seattle, WA, USA (2009):S21.004.
112. Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, Yoshio T, Masuyama J, Fujimura A, Kobayashi E, Kano S, Minota S: Effects of FTY720 in MRL-lpr/lpr mice: Therapeutic potential in systemic lupus erythematosus. J Rheumatol (2002) 29(4):707-716.
113. Suzuki S, Li XK, Shinomiya T, Enosawa S, Amemiya H, Amari M, Naoe S: The in vivo induction of lymphocyte apoptosis in MRL-lpr/lpr mice treated with FTY720. Clin Exp Immunol (1997) 107(1):103-111.
114. Alperovich G, Rama I, Lloberas N, Franquesa M, Poveda R, Gomà M, Herrero-Fresneda I, Cruzado JM, Bolaños N, Carrera M, Grinyó JM et al: New immunosuppresor strategies in the treatment of murine lupus nephritis. Lupus (2007) 16(1):18-24.
115. Maki T, Gottschalk R, Ogawa N, Monaco AP: Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720. Transplantation (2005) 79(9):1051-1055.
116. Kataoka H, Sugahara K, Shimano K, Teshima K, Koyama M, Fukunari A, Chiba K: FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infltration. Cell Mol Immunol (2005) 2(6):439-448.
117. Kitabayashi H, Isobe M, Watanabe N, Suzuki J, Yazaki Y, Sekiguchi M: FTY720 prevents development of experimental autoimmune myocarditis through reduction of circulating lymphocytes. J Cardiovasc Pharmacol (2000) 35(3):410-416.
118. Kurose S, Ikeda E, Tokiwa M, Hikita N, Mochizuki M: Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats. Exp Eye Res (2000) 70(1): 7-15.
119. Fujii T, Tomita T, Kanai T, Nemoto Y, Totsuka T, Sakamoto N, Nakamura T, Tsuchiya K, Okamoto R, Watanabe M: FTY720 suppresses the development of colitis in lymphoid-null mice by modulating the traffcking of colitogenic CD4+ T cells in bone marrow. Eur J Immunol (2008) 38(12):3290-3303.
120. Matsuura M, Imayoshi T, Okumoto T: Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats. Int J Immunopharmacol (2000) 22(4):323-331.
121. Wang F, Tan W, Guo D, He S: Reduction of CD4+ T cells and improvement of pathological changes of collagen-induced arthritis by FTY720. Eur J Pharmacol (2007) 573(1-3):230-240.
122. Kitano M, Hla T, Sekiguchi M, Kawahito Y, Yoshimura R, Miyazawa K, Iwasaki T, Sano H, Saba JD, Tam YY: Sphingosine 1-phosphate/ sphingosine 1-phosphate receptor 1 signaling in rheumatoid synovium: Regulation of synovial proliferation and infammatory gene expression. Arthritis Rheum (2006) 54(3): 742-753.
123. Zhao C, Fernandes MJ, Turgeon M, Tancrède S, Di Battista J, Poubelle PE, Bourgoin SG: Specifc and overlapping sphingosine-1-phosphate receptor functions in human synoviocytes: Impact of TNF-?. J Lipid Res (2008) 49(11):2323-2337.
124. Ogawa R, Takahashi M, Hirose S, Morimoto H, Ise H, Murakami T, Yasue T, Kuriyama K, Hongo M, Kobayashi E, Ikeda U: A novel sphingosine-1-phosphate receptor agonist KRP-203 attenuates rat autoimmune myocarditis. Biochem Biophys Res Commun (2007) 361(3):621-628.
125. Kaneko T, Murakami T, Kawana H, Takahashi M, Yasue T, Kobayashi E: Sphingosine-1-phosphate receptor agonists suppress concanavalin A-induced hepatic injury in mice. Biochem Biophys Res Commun (2006) 345(1):85-92.
126. Wenderfer SE, Stepkowski SM, Braun MC: Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist. Kidney Int (2008) 74(10):1319-1326.
127. Song J, Matsuda C, Kai Y, Nishida T, Nakajima K, Mizushima T, Kinoshita M, Yasue T, Sawa Y, Ito T: A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-defcient mice. J Pharmacol Exp Ther (2008) 324(1):276-283.
128. Gonzalez-Cabrera PJ, Jo E, Sanna MG, Brown S, Leaf N, Marsolais D, Schaeffer MT, Chapman J, Cameron M, Guerrero M, Roberts E et al: Full pharmacological effcacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions. Mol Pharmacol (2008) 74(5):1308-1318.
129. Whetzel AM, Bolick DT, Srinivasan S, Macdonald TL, Morris MA
130. Ley K, Hedrick CC: Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor. Circ Res (2006) 99(7):731-739.